Extended Research Article
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262):clinical effectiveness systematic review and economic model
Rachel Archer
,
Paul Tappenden
,
Shijie Ren
,
Marrissa Martyn-St James
,
Rebecca Harvey
,
Hasan Basarir
et al.
-
Journal:
Health Technology Assessment Volume: 20, Issue: 39
-
Published:
24 May 2016